What Деготь Treats: Main Uses and Benefits

The preparation may be relevant for symptom management in conditions involving recurrent or episodic manifestations, applied across conditions involving pronounced symptoms such as psoriasis and eczema. It is used as part of symptomatic management in conditions involving inflammatory or irritative states. It supports the patient during difficult episodes by easing distress related to physical discomfort, such as itching (pruritus), redness, and skin scaling associated with these chronic conditions.

---

Birch Tar may be part of symptomatic management in settings marked by heightened patient distress, and helps improve day-to-day comfort during symptomatic periods. It is relevant for managing symptoms that interfere with daily comfort, and may assist with maintaining functional stability during symptomatic periods. The agent is commonly used to help with symptom management in conditions presenting with systemic or localized discomfort, such as excessive oiliness (seborrhea), dandruff, and minor surface imperfections like acne breakouts. It supports general well-being during symptomatic phases.

---

Quick Fact: Relief for Itching and Scaling

The preparation is relevant for easing challenging symptoms associated with chronic conditions and is commonly used to help address clusters of symptoms that interfere with daily comfort.

Eligibility Profile for Деготь (Birch Tar)

Official regulatory information for topical tar preparations defines strict eligibility criteria and contraindications for use. The preparation is generally allowed for adults and children aged 12 years and over for approved topical conditions. Children aged 6–12 years should only use the product under medical supervision, while use in children under 6 years and infants is not recommended.

---

Contraindicated Populations and Conditions

Classification	Population or Condition
Absolute Contraindication	Known hypersensitivity or allergy to Birch Tar or other components.
Absolute Contraindication	Patients with diseases characterized by photosensitivity, such as Lupus Erythematosus.
Application Prohibited	Application to infected, raw, oozing, or blistered skin lesions.

---

Restricted or Conditional Use

Use is restricted in pregnant and breastfeeding women due to insufficient human safety data; avoidance is recommended, especially during the first trimester. Furthermore, use is generally prohibited on the anogenital area and mucous membranes without specific medical direction. Safety and efficacy are generally not established for the overall pediatric population under 12 years of age.

Interactions with other medicines and products

As a substance intended exclusively for external use, the officially documented interactions for Birch Tar (Oleum Rusci) are confined to local effects on the skin and interaction with other topical agents. Regulatory information confirms that due to its minimal systemic absorption, Birch Tar is not associated with the complex pharmacokinetic interactions—such as those involving CYP enzymes or drug transporters—that affect systemic medicines. Consequently, there are no specific oral or injectable medicines formally classified as contraindicated combinations in regulatory documents.

The primary interaction patterns are pharmacodynamic and local:

• Topical Agents: Co-administration with other strong keratolytic or irritant topical preparations is restricted. Regulatory guidance notes an additive risk of local skin irritation or pronounced discomfort when combined with substances like Salicylic Acid.
• Photosensitivity: There is a documented risk of additive photosensitivity. Therefore, its use is constrained in combination with treatments that cause sensitivity to light, including phototherapy or exposure to UV light.

Because of this local risk, an administration timing rule applies: the regulatory label mandates the separation of application times between Birch Tar and other medicinal topical treatments to manage the potential for reinforced local effects.

The mechanism of action for Деготь centers on molecular modulation of inflammatory and cellular proliferation pathways.

The compounds in Деготь modulate the NF-kappa B signaling pathway, primarily through the inhibition of Ikappa B kinase ( IKK) activity. This molecular interaction reduces the nuclear translocation of the NF-kappa B complex, leading to a consequent decrease in the transcription and secretion of key pro-inflammatory cytokines, including TNF-alpha, IL-1beta, and IL-6.

Furthermore, components of Деготь induce the expression of genes associated with keratinocyte differentiation and epidermal barrier formation, such as filaggrin and loricrin. This effect accelerates the maturation of the stratum corneum. The substance also exhibits a direct interaction with the aryl hydrocarbon receptor ( AhR), influencing downstream transcriptional events related to cellular growth and differentiation.

Instruction Map: How to use Деготь — Official Administration Guidelines

---

Administration Scope

Parameter	Instruction
Route of administration	Topical (External Use Only) is the single approved route, applied directly to the skin or scalp.
Dosing schedule	Application involves using a small amount sufficient to cover the affected area. For certain preparations, a specific 1 mm layer may be instructed.
Timing in relation to meals (if applicable)	Not applicable, as the route of administration is topical.
Preparation requirements (if applicable)	Liquid formulations must be shaken well before use. Specialized washes mandate a specified contact time on the scalp before rinsing.
Age-group administration rules	Use in children is generally not recommended for those under six years of age. For children aged 6 to 12 years, use is directed under medical supervision only for analogous tar preparations.
Missed-dose rules	Not specified in standard labeling; use is flexible and application frequency is intermittent.
Special procedural conditions	The preparation must strictly avoid contact with the eyes and mucous membranes. Application is to be repeated according to the prescribed frequency.

---

Instruction Classifications (High-Level)

Classification	Description
Administration method type	Topical
Frequency pattern	Intermittent / As-needed for maintenance, or up to four times daily for initial treatment with ointments.
Use-context constraints	Duration Constraint: The product is not for prolonged continuous use without professional guidance.

---

Resulting procedural structure

Official step sequence:

• Shake the liquid formulation well before use.
• Apply the directed amount to the affected area, avoiding sensitive zones.
• Observe the required contact time (e.g., several minutes) before rinsing the wash/shampoo preparations.
• Repeat application as directed, from twice weekly up to four times daily.

Connection to the overall use protocol (2–4 sentences): The official instructions establish a time-controlled topical protocol where the route is strictly limited to the external surface of the body. Proper use is defined by adhering to a specific intermittent frequency pattern and following preparatory steps such as shaking the product and observing a required contact time. This collective structure dictates the standardized manner in which the substance is to be applied.

Research evidence / Overview of studies for Деготь

Evidence for Use in Psoriasis

Research has historically explored the application of topical tar preparations, including birch tar, for conditions such as plaque-type psoriasis. The available data consists primarily of older, smaller-scale clinical trials and a limited number of short-term Randomized Controlled Trials (RCTs). These studies monitored measurements of disease severity scores, as well as measures linked to inflammatory or irritative states such as skin scaling and itching. The study populations were generally adults with conditions where symptoms may vary in intensity.

The trials described patterns observed in the tracking of measurements of disease severity over the short duration of the research. However, the evidence base is characterized as limited and heterogeneous, largely due to variability in the specific types of tar preparations used, which include coal, pine, and birch tar. A main limitation is the absence of a substantial base of large, modern, placebo-controlled RCTs specifically focused on standardized birch tar preparations.

---

Evidence for Use in Eczema (Atopic Dermatitis)

Research was studied for birch tar preparations in the context of conditions such as eczema or atopic dermatitis. This research primarily consists of a few pilot studies, small comparative trials, and crossover designs, with high-quality, large-scale RCTs being scarce. Researchers examined outcomes such as disease activity scores (e.g., SCORAD), which relate to daily functioning, as well as patient-reported outcomes describing perceived discomfort such as itching and inflammation.

Few high-quality, placebo-controlled RCTs are available, which means the evidence is limited when attempting to draw specific conclusions about standardized birch tar preparations for this condition. The data are still emerging, and certainty remains low because follow-up durations were limited to short treatment periods. The research base appears to rely significantly on older reports or extrapolation from data concerning similar wood tar products.

---

Evidence for the Refined Birch Bark Extract in Wound Management

It is important to note that a separate, specific, refined derivative of birch bark extract has been the subject of structured study for use in the context of chronic wounds. This research differs significantly from the evidence available for the traditional, crude Деготь preparation. The foundation for this specific preparation includes pivotal Phase III Randomized Controlled Trials (RCTs) that were double-blind and controlled.

The primary evidence, which is supported by controlled trials, applies exclusively to a purified and standardized pharmaceutical-grade extract, and these results apply only to the populations studied with this specific derivative and cannot be directly extrapolated to the traditional, crude Деготь preparation. The data is limited to specific, rare chronic wound types.

Common questions about Деготь (FAQ)

Q: Is Деготь the same as coal tar?

No. Official documents specify that Деготь, or Oleum Rusci, is Birch Tar, a natural substance derived from the bark of the Birch tree. Coal tar is a chemically distinct substance that comes from coal processing. The two substances are understood to be different in their origin and precise chemical makeup.

---

Q: Are there different types of Деготь used in medicine?

In regulatory contexts, the term refers specifically to Birch Tar (Oleum Rusci), which is distinct from other therapeutic tars like pine tar or coal tar due to its specific origin and chemical composition.

---

Q: What is the difference between Деготь and pine tar?

Official information indicates that Деготь (Birch Tar) is derived exclusively from birch bark (Betula species). In contrast, pine tar is a separate product derived from the wood and roots of pine trees. Although both are used topically, their distinct plant origins result in different chemical compositions.

---

Q: Does Деготь interact with common skin moisturizers?

Regulatory documents do not specifically list common cosmetic moisturizers, but they note the potential for local effects when combined with other topical treatments and preparations that are irritating. Official guidance describes the separation of application times between Birch Tar and other medicinal topical products.

---

Q: Can Деготь be used by people with sensitive skin?

Official safety data notes the possibility of localized skin irritation, dermatitis, or redness (erythema). Its use is strictly prohibited on raw, oozing, or blistered skin lesions. Given the risk of local irritation, regulatory information highlights the need for careful consideration when using the product, particularly for individuals with generally sensitive skin.

---

Q: Does Деготь contain any ingredients that are related to coal?

No. The official composition of Деготь is strictly defined as a natural-origin product derived from birch bark. Its active properties come from organic compounds unique to birch, such as guaiacol and creosol, and it does not contain components related to coal processing.

---

Q: Can Деготь be used together with corticosteroid creams?

Regulatory guidance includes a restriction on co-administration with other medicinal topical treatments. To manage the risk of reinforced local effects, official labeling defines the need for a separation of application times between Birch Tar and other topical medications.

---

Q: What is the role of Деготь in treating dandruff?

Although dandruff may not be listed as a primary indication, the product is approved for use on the scalp and is used for conditions involving scaling skin. Its classification as an antiseptic and dermatological preparation is consistent with its use in managing surface impurities and assisting in the relief of localized discomfort on the scalp.

---

Q: Can Деготь cause a burning sensation?

The official safety profile lists the potential for side effects such as localized skin irritation and pronounced discomfort. Although a specific 'burning' sensation is not always listed by name, it is a type of local irritation covered within the general description of possible adverse reactions.

---

Q: What should be done if an allergic reaction is suspected?

Official regulatory information specifies that a known hypersensitivity (severe allergic-type reaction) to Birch Tar is an absolute reason not to use the product. Due to the clinical seriousness of hypersensitivity reactions, regulatory information highlights them as a major safety concern requiring prompt professional medical evaluation.

---

Q: Is there evidence about Деготь’s effect on hair?

Official safety data lists potential adverse reactions on the hair itself. These include the possibility of alopecia (hair loss) and changes in hair color or texture. The product’s purpose is generally defined for use on the skin and scalp for scaling conditions, and its official documents do not describe a role in promoting hair growth.

---

Q: Is Деготь mentioned in official drug lists for Psoriasis?

Regulatory documents indicate that topical tar preparations, including Birch Tar, are historically explored and used in the management of scaling skin conditions. The use in conditions like psoriasis is referenced in official overviews of research.

---

Q: Do different forms (soap, cream, shampoo) of Деготь product have different uses?

The official instructions differentiate the application method based on the product form. For example, specialized washes require a specified contact time on the scalp before rinsing, while ointments are applied and left on the skin. The overall approved route remains strictly topical.

---

Q: How long has Деготь been mentioned in research?

Supporting research summaries reference the use of topical tar preparations in historical research and mention reliance on older, smaller-scale clinical trials. This indicates that the substance has a long, established history of study in dermatological science.

How to Store and Dispose of Деготь (Birch Tar)

Official regulatory guidelines strictly define the conditions for storing and disposing of Birch Tar to maintain its stability and ensure safety.

---

Storage Requirements

Condition	Requirement
Temperature Range	Store between mathbf5^circ to mathbf25^circC (41^circ to 77^circF).
Environmental Protection	Keep in a dry, dark place and protect from direct sunlight and heat or sources of ignition.
Container Rule	Keep the container tightly closed. Opened containers must be carefully resealed and stored upright.
Safety Restriction	Store out of the sight and reach of children (store locked up).

---

Disposal Instructions

Disposal must be directed to an approved waste disposal plant. The product must not be flushed into surface water or the sanitary sewer system. Spills must be contained and collected according to local waste handling regulations.